Literature DB >> 12819074

Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge.

Alyson Yoder1, Xiaohui Wang, Ying Ma, Mario T Philipp, Marta Heilbrun, John H Weis, Carsten J Kirschning, R Mark Wooten, Janis J Weis.   

Abstract

Toll-like receptor 2 (TLR2) is a transmembrane signal transducer for tripalmitoyl-S-glyceryl-cysteine (Pam(3)Cys)-modified lipoproteins, including OspA from the Lyme disease spirochete Borrelia burgdorferi. The Pam(3)Cys modification provides adjuvant activity for inducing humoral responses, suggesting that TLR2 could function as the adjuvant receptor for the OspA vaccine. The importance of TLR2 in the humoral response to OspA was confirmed, because overall levels of immunoglobulin G (IgG) were reduced in TLR2-deficient mice, when compared with those in wild-type mice. However, the levels of production of IgG1 were similar in both mouse strains, and the levels of induction of protective immunity were comparable. Unlipidated OspA was not immunogenic in wild-type or TLR2-deficient mice, indicating the lipid modification was active in the absence of TLR2. These findings indicate that the Pam(3)Cys modification of bacterial lipoprotein has adjuvant properties independent of TLR2 signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819074      PMCID: PMC161983          DOI: 10.1128/IAI.71.7.3894-3900.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

2.  Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism.

Authors:  C Werts; R I Tapping; J C Mathison; T H Chuang; V Kravchenko; I Saint Girons; D A Haake; P J Godowski; F Hayashi; A Ozinsky; D M Underhill; C J Kirschning; H Wagner; A Aderem; P S Tobias; R J Ulevitch
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

3.  Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling.

Authors:  Y Bulut; E Faure; L Thomas; O Equils; M Arditi
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

4.  Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi.

Authors:  R Mark Wooten; Ying Ma; R Alyson Yoder; Jeanette P Brown; John H Weis; James F Zachary; Carsten J Kirschning; Janis J Weis
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

5.  Specific antibodies elicited by antigen covalently linked to a synthetic adjuvant.

Authors:  W G Bessler; B Suhr; H J Bühring; C P Muller; K H Wiesmüller; G Becker; G Jung
Journal:  Immunobiology       Date:  1985-09       Impact factor: 3.144

6.  Lyme disease-a tick-borne spirochetosis?

Authors:  W Burgdorfer; A G Barbour; S F Hayes; J L Benach; E Grunwaldt; J P Davis
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

7.  Lyme borreliosis in selected strains and ages of laboratory mice.

Authors:  S W Barthold; D S Beck; G M Hansen; G A Terwilliger; K D Moody
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

8.  Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins.

Authors:  Osamu Takeuchi; Shintaro Sato; Takao Horiuchi; Katsuaki Hoshino; Kiyoshi Takeda; Zhongyun Dong; Robert L Modlin; Shizuo Akira
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

9.  Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.

Authors:  Lena Alexopoulou; Venetta Thomas; Markus Schnare; Yves Lobet; Juan Anguita; Robert T Schoen; Ruslan Medzhitov; Erol Fikrig; Richard A Flavell
Journal:  Nat Med       Date:  2002-07-01       Impact factor: 53.440

10.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

Authors:  A H Ding; C F Nathan; D J Stuehr
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

View more
  11 in total

1.  Mitogenicity of the recombinant mycobacterial 27-kilodalton lipoprotein is not connected to its antiprotective effect.

Authors:  Avi-Hai Hovav; Liuba Davidovitch; Gabriel Nussbaum; Jacob Mullerad; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Expression and secretion of recombinant outer-surface protein A from the Lyme disease agent, Borrelia burgdorferi, in Nicotiana tabacum suspension cells.

Authors:  Catherine Navarre; Mélanie Delannoy; Benoit Lefebvre; Joseph Nader; Delphine Vanham; Marc Boutry
Journal:  Transgenic Res       Date:  2006-06       Impact factor: 2.788

Review 3.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.

Authors:  Charles Maisonneuve; Sylvie Bertholet; Dana J Philpott; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 4.  Toll or toll-free adjuvant path toward the optimal vaccine development.

Authors:  Ken J Ishii; Shizuo Akira
Journal:  J Clin Immunol       Date:  2007-03-17       Impact factor: 8.317

5.  Adenoviral delivery of interleukin-10 fails to attenuate experimental Lyme disease.

Authors:  Charles R Brown; Annie Y-C Lai; Steven T Callen; Victoria A Blaho; Jennifer M Hughes; William J Mitchell
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

Review 6.  Outer membrane proteins of pathogenic spirochetes.

Authors:  Paul A Cullen; David A Haake; Ben Adler
Journal:  FEMS Microbiol Rev       Date:  2004-06       Impact factor: 16.408

7.  Viable Borrelia burgdorferi enhances interleukin-10 production and suppresses activation of murine macrophages.

Authors:  John J Lazarus; Maria A Kay; Akisha L McCarter; R Mark Wooten
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

Review 8.  Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease.

Authors:  Purnima Bhanot; Nikhat Parveen
Journal:  Int J Parasitol       Date:  2018-10-24       Impact factor: 3.981

9.  NERVE: new enhanced reverse vaccinology environment.

Authors:  Sandro Vivona; Filippo Bernante; Francesco Filippini
Journal:  BMC Biotechnol       Date:  2006-07-18       Impact factor: 2.563

Review 10.  Host transcriptome response to Borrelia burgdorferi sensu lato.

Authors:  Derick Thompson; John A Watt; Catherine A Brissette
Journal:  Ticks Tick Borne Dis       Date:  2020-12-13       Impact factor: 3.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.